[
  {
    "ts": "2025-11-06T00:17:00+00:00",
    "headline": "Metsera Issues Statement in Response to Litigation Ruling",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer:",
    "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-001700501.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "ebd6390c-f1c4-3d4c-b2d8-489e9fb81f96",
      "content": {
        "id": "ebd6390c-f1c4-3d4c-b2d8-489e9fb81f96",
        "contentType": "STORY",
        "title": "Metsera Issues Statement in Response to Litigation Ruling",
        "description": "",
        "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer:",
        "pubDate": "2025-11-06T00:17:00Z",
        "displayTime": "2025-11-06T00:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/002971877c90ea768734c7a4e3df9643",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z7CW4Z46Q2d4F1vTH__5lQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/002971877c90ea768734c7a4e3df9643.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wzye6TKdasyqeLHD2xk0hA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/002971877c90ea768734c7a4e3df9643.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-001700501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-001700501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T09:10:00+00:00",
    "headline": "2 Dirt Cheap Stocks to Buy With $1,000 Right Now",
    "summary": "With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty.",
    "url": "https://www.fool.com/investing/2025/11/06/2-dirt-cheap-stocks-to-buy-with-1000-right-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "5615feb5-6c3e-3a65-ad06-568c114dbebb",
      "content": {
        "id": "5615feb5-6c3e-3a65-ad06-568c114dbebb",
        "contentType": "STORY",
        "title": "2 Dirt Cheap Stocks to Buy With $1,000 Right Now",
        "description": "",
        "summary": "With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty.",
        "pubDate": "2025-11-06T09:10:00Z",
        "displayTime": "2025-11-06T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/01fe851bf89a3eed00a2ec516398c647",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A hand drawing a scale showing price vs. value.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bjvWPQ8qSc5iNf1JBeK6ng--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/01fe851bf89a3eed00a2ec516398c647.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jsUqAMpZNKb_qReqgqwWEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/01fe851bf89a3eed00a2ec516398c647.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/06/2-dirt-cheap-stocks-to-buy-with-1000-right-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-dirt-cheap-stocks-buy-091000853.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UPS"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T09:44:00+00:00",
    "headline": "Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting",
    "summary": "Pfizer just gave income investors four reasons to like its juicy dividend even more.",
    "url": "https://www.fool.com/investing/2025/11/06/why-pfizers-7-yielding-dividend-just-got-safer/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b9044c1c-6543-3d72-a473-cf7442698a7c",
      "content": {
        "id": "b9044c1c-6543-3d72-a473-cf7442698a7c",
        "contentType": "STORY",
        "title": "Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting",
        "description": "",
        "summary": "Pfizer just gave income investors four reasons to like its juicy dividend even more.",
        "pubDate": "2025-11-06T09:44:00Z",
        "displayTime": "2025-11-06T09:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/a69ea8cbe042d77832ac0e4077716253",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "Pfizer logo.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9t2a..G1A6OOwqV71Gd20A--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/a69ea8cbe042d77832ac0e4077716253.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9P_dp5vvUcyDyxq66umFA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a69ea8cbe042d77832ac0e4077716253.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/06/why-pfizers-7-yielding-dividend-just-got-safer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizers-7-yielding-dividend-094400797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:11:57+00:00",
    "headline": "Pfizer Responds to Court Decision Rejecting Request to Temporary Halt Metsera-Novo Nordisk Deal",
    "summary": "Pfizer (PFE) said late Wednesday that it will continue to pursue its legal and antitrust claims agai",
    "url": "https://finance.yahoo.com/news/pfizer-responds-court-decision-rejecting-111157609.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "cc1189f9-664c-3faa-b9eb-48c30d89a751",
      "content": {
        "id": "cc1189f9-664c-3faa-b9eb-48c30d89a751",
        "contentType": "STORY",
        "title": "Pfizer Responds to Court Decision Rejecting Request to Temporary Halt Metsera-Novo Nordisk Deal",
        "description": "",
        "summary": "Pfizer (PFE) said late Wednesday that it will continue to pursue its legal and antitrust claims agai",
        "pubDate": "2025-11-06T11:11:57Z",
        "displayTime": "2025-11-06T11:11:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-responds-court-decision-rejecting-111157609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-responds-court-decision-rejecting-111157609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T10:07:39+00:00",
    "headline": "Stocks to Watch Thursday: Tesla, Robinhood, Metsera, Snap",
    "summary": "üîé Tesla (TSLA): The electric-vehicle maker will reveal if shareholders approved a $1 trillion pay package for CEO Elon Musk. They are also voting on whether Tesla should invest in Musk's xAI startup.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
      "content": {
        "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
        "contentType": "STORY",
        "title": "Stocks to Watch Thursday: Tesla, Robinhood, Metsera, Snap",
        "description": "",
        "summary": "üîé Tesla (TSLA): The electric-vehicle maker will reveal if shareholders approved a $1 trillion pay package for CEO Elon Musk. They are also voting on whether Tesla should invest in Musk's xAI startup.",
        "pubDate": "2025-11-06T10:07:39Z",
        "displayTime": "2025-11-06T10:07:39Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a1ff4ab9-5bf1-31bc-a536-a49e1309d556/stocks-to-watch-thursday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zeifGFITRZDScQ8nFl9wgQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FeUttjJqxCTNJvBjDtiFGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "AMSYF"
            },
            {
              "symbol": "MT"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "DUOL"
            },
            {
              "symbol": "XAAI.PVT"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "QCOM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T13:09:23+00:00",
    "headline": "Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges",
    "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finance.yahoo.com/news/live/earnings-live-moderna-stock-pops-amid-cost-cutting-efforts-snap-stock-soars-duolingo-plunges-130923384.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "035a1404-14a9-4292-96b8-08cca27526ee",
      "content": {
        "id": "035a1404-14a9-4292-96b8-08cca27526ee",
        "contentType": "STORY",
        "title": "Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges",
        "description": "",
        "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
        "pubDate": "2025-11-06T13:09:23Z",
        "displayTime": "2025-11-06T13:24:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/9800e900-bb11-11f0-b7fd-92ce250976c9",
          "originalWidth": 3293,
          "originalHeight": 2195,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hb7SHXWVJnJ83O2OvrHuUg--~B/aD0yMTk1O3c9MzI5MzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/9800e900-bb11-11f0-b7fd-92ce250976c9.cf.webp",
              "width": 3293,
              "height": 2195,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yfFUaouzIWGqdWupA5VjWQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/9800e900-bb11-11f0-b7fd-92ce250976c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-moderna-stock-pops-amid-cost-cutting-efforts-snap-stock-soars-duolingo-plunges-130923384.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-moderna-stock-pops-amid-cost-cutting-efforts-snap-stock-soars-duolingo-plunges-130923384.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "DUOL"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "DASH"
            },
            {
              "symbol": "SMCI"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "ARM"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MCD"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "ABNB"
            },
            {
              "symbol": "CEG"
            },
            {
              "symbol": "MAR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:51:28+00:00",
    "headline": "AstraZeneca CEO bullish on record revenue numbers and US growth",
    "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
    "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
      "content": {
        "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
        "contentType": "VIDEO",
        "title": "AstraZeneca CEO bullish on record revenue numbers and US growth",
        "description": "<p>AstraZeneca's (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/AZN\">AZN</a>, <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.L\">AZN.L</a>, <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.ST\">AZN.ST</a>) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>), Merck (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MRK\">MRK</a>) and Pfizer (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>). For more live coverage of the markets, watch the full episode of <em>Market Sunrise</em> and visit<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/\"> Yahoo Finance</a>.</p>",
        "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
        "pubDate": "2025-11-06T12:51:28Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab",
          "originalWidth": 4787,
          "originalHeight": 2695,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YZigCM3MtAH584LADKiEmA--~B/aD0yNjk1O3c9NDc4NzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 4787,
              "height": 2695,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lb3cKjiVc_C_ZhL48TzyZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T13:01:00+00:00",
    "headline": "Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results",
    "summary": "Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-",
    "url": "https://finance.yahoo.com/news/sangamo-therapeutics-reports-recent-business-130100259.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "543d5646-8a38-3446-8b21-14bc790190d4",
      "content": {
        "id": "543d5646-8a38-3446-8b21-14bc790190d4",
        "contentType": "STORY",
        "title": "Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results",
        "description": "",
        "summary": "Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-",
        "pubDate": "2025-11-06T13:01:00Z",
        "displayTime": "2025-11-06T13:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/4c688b7fb4ce4aa527a538b9e9e8070b",
          "originalWidth": 3087,
          "originalHeight": 763,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yzeT2Jcm2HBwFKLnggPVYg--~B/aD03NjM7dz0zMDg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4c688b7fb4ce4aa527a538b9e9e8070b.cf.webp",
              "width": 3087,
              "height": 763,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m5bK_.5Yf1_ZofvSRERU2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4c688b7fb4ce4aa527a538b9e9e8070b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sangamo-therapeutics-reports-recent-business-130100259.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sangamo-therapeutics-reports-recent-business-130100259.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SGMO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:29:00+00:00",
    "headline": "Moderna Swings to a Loss. The Stock Jumps Anyway.",
    "summary": "Shares of  Moderna  rose sharply Thursday after the vaccine company reported better-than-expected quarterly results and narrowed its full-year guidance.  Moderna  posted a loss of 51 cents a share for the third quarter, down from a profit of 3 cents last year, but narrower than analysts‚Äô consensus calls for a loss of $2.12.  The company also said it now expects 2025 revenue of $1.6 billion to $2 billion, compared to a previous range of $1.5 billion to $2.2 billion.",
    "url": "https://www.barrons.com/articles/moderna-stock-earnings-preview-51975438?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "0b5bfd14-9904-3099-a0a9-8b9596ae958e",
      "content": {
        "id": "0b5bfd14-9904-3099-a0a9-8b9596ae958e",
        "contentType": "STORY",
        "title": "Moderna Swings to a Loss. The Stock Jumps Anyway.",
        "description": "",
        "summary": "Shares of  Moderna  rose sharply Thursday after the vaccine company reported better-than-expected quarterly results and narrowed its full-year guidance.  Moderna  posted a loss of 51 cents a share for the third quarter, down from a profit of 3 cents last year, but narrower than analysts‚Äô consensus calls for a loss of $2.12.  The company also said it now expects 2025 revenue of $1.6 billion to $2 billion, compared to a previous range of $1.5 billion to $2.2 billion.",
        "pubDate": "2025-11-06T12:29:00Z",
        "displayTime": "2025-11-06T12:29:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0b5bfd14-9904-3099-a0a9-8b9596ae958e/moderna-swings-to-a-loss-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/749fjdDNHOZZaiWMxvk7TQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rrBpMbNzvxDHGSjZc1Bgxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/moderna-stock-earnings-preview-51975438?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:00:00+00:00",
    "headline": "Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases",
    "summary": "Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (‚ÄúAccipiter Bio‚Äù), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with",
    "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "792a147e-6e7a-3d78-b07e-d02a2f3dc5c7",
      "content": {
        "id": "792a147e-6e7a-3d78-b07e-d02a2f3dc5c7",
        "contentType": "STORY",
        "title": "Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases",
        "description": "",
        "summary": "Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (‚ÄúAccipiter Bio‚Äù), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with",
        "pubDate": "2025-11-06T12:00:00Z",
        "displayTime": "2025-11-06T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c",
          "originalWidth": 2404,
          "originalHeight": 669,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TczC315ovJ4ZaOckt0ONjA--~B/aD02Njk7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c.cf.webp",
              "width": 2404,
              "height": 669,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nwHooGBhqjyBZ5rEFHWJnA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:00:00+00:00",
    "headline": "C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
    "summary": "Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 ¬µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomid",
    "url": "https://finance.yahoo.com/news/c4-therapeutics-reports-third-quarter-120000313.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c4685d8c-ce4c-3909-bc17-3f1bec31a76a",
      "content": {
        "id": "c4685d8c-ce4c-3909-bc17-3f1bec31a76a",
        "contentType": "STORY",
        "title": "C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
        "description": "",
        "summary": "Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 ¬µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomid",
        "pubDate": "2025-11-06T12:00:00Z",
        "displayTime": "2025-11-06T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d0dfe2d0cea5566d521085e071900a8d",
          "originalWidth": 1002,
          "originalHeight": 150,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B0S9UMNaqszRoii9p9Qo9A--~B/aD0xNTA7dz0xMDAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d0dfe2d0cea5566d521085e071900a8d.cf.webp",
              "width": 1002,
              "height": 150,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G8SV39wV81QSgpSKqshtEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d0dfe2d0cea5566d521085e071900a8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/c4-therapeutics-reports-third-quarter-120000313.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/c4-therapeutics-reports-third-quarter-120000313.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CCCC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:46:47+00:00",
    "headline": "Pfizer Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions",
    "summary": "The third-quarter results for Pfizer Inc. ( NYSE:PFE ) were released last week, making it a good time to revisit its...",
    "url": "https://finance.yahoo.com/news/pfizer-inc-just-beat-analyst-114647391.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4d9d5a00-aa2c-381e-84fb-a038998d0f67",
      "content": {
        "id": "4d9d5a00-aa2c-381e-84fb-a038998d0f67",
        "contentType": "STORY",
        "title": "Pfizer Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions",
        "description": "",
        "summary": "The third-quarter results for Pfizer Inc. ( NYSE:PFE ) were released last week, making it a good time to revisit its...",
        "pubDate": "2025-11-06T11:46:47Z",
        "displayTime": "2025-11-06T11:46:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-just-beat-analyst-114647391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-just-beat-analyst-114647391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T08:00:00+00:00",
    "headline": "Why Pfizer and Novo are duking it out over weight loss startup Metsera",
    "summary": "A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena‚Äôs high stakes.",
    "url": "https://www.pharmavoice.com/news/pfizer-novo-nordisk-metsera-weight-loss-deal-billions/804804/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "f6f639ff-4fde-364d-abd6-7fc48b7ca648",
      "content": {
        "id": "f6f639ff-4fde-364d-abd6-7fc48b7ca648",
        "contentType": "STORY",
        "title": "Why Pfizer and Novo are duking it out over weight loss startup Metsera",
        "description": "",
        "summary": "A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena‚Äôs high stakes.",
        "pubDate": "2025-11-06T08:00:00Z",
        "displayTime": "2025-11-06T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/513c8dc3abab8ce2dd0a04c236cee51c",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.YZIZjg8LJrU3SxCnuMBNA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/513c8dc3abab8ce2dd0a04c236cee51c.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F.bI.0tojD92WU2Ik17KtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/513c8dc3abab8ce2dd0a04c236cee51c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/pfizer-novo-nordisk-metsera-weight-loss-deal-billions/804804/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizer-novo-duking-over-080000979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T15:23:00+00:00",
    "headline": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
    "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
    "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
      "content": {
        "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
        "contentType": "STORY",
        "title": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
        "description": "",
        "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
        "pubDate": "2025-11-06T15:23:00Z",
        "displayTime": "2025-11-06T15:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T15:11:02+00:00",
    "headline": "'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera",
    "summary": "Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.",
    "url": "https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-bidding-battle/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "30d601c1-eec6-326d-8701-297c702df92a",
      "content": {
        "id": "30d601c1-eec6-326d-8701-297c702df92a",
        "contentType": "STORY",
        "title": "'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera",
        "description": "",
        "summary": "Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.",
        "pubDate": "2025-11-06T15:11:02Z",
        "displayTime": "2025-11-06T15:11:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/30d601c1-eec6-326d-8701-297c702df92a/-it-s-getting-ugly-analyst.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/2fccbfe6aac3dec431e84fc1f51c045e",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eR8gS3muy97F9Yo6DVNwmg--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/2fccbfe6aac3dec431e84fc1f51c045e.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wU7ZjrZ0sbgksyDvqKswxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/2fccbfe6aac3dec431e84fc1f51c045e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-bidding-battle/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T14:39:16+00:00",
    "headline": "Stocks to Watch Thursday: Marvell, AppLovin, Qualcomm,  Tesla",
    "summary": "‚ÜóÔ∏è Tesla (TSLA): The electric-vehicle maker will reveal if shareholders approved a $1 trillion pay package for CEO Elon Musk. They are also voting on whether Tesla should invest in Musk's xAI startup.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
      "content": {
        "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
        "contentType": "STORY",
        "title": "Stocks to Watch Thursday: Marvell, AppLovin, Qualcomm,  Tesla",
        "description": "",
        "summary": "‚ÜóÔ∏è Tesla (TSLA): The electric-vehicle maker will reveal if shareholders approved a $1 trillion pay package for CEO Elon Musk. They are also voting on whether Tesla should invest in Musk's xAI startup.",
        "pubDate": "2025-11-06T14:39:16Z",
        "displayTime": "2025-11-06T14:39:16Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a1ff4ab9-5bf1-31bc-a536-a49e1309d556/stocks-to-watch-thursday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zeifGFITRZDScQ8nFl9wgQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FeUttjJqxCTNJvBjDtiFGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "DUOL"
            },
            {
              "symbol": "DASH"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "9984.T"
            },
            {
              "symbol": "DDOG"
            },
            {
              "symbol": "XAAI.PVT"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:39:36+00:00",
    "headline": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall",
    "summary": "The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.",
    "url": "https://uk.finance.yahoo.com/news/astrazeneca-us-investment-new-york-listing-163936444.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "9aba44ce-6377-42df-af30-a766c5758c13",
      "content": {
        "id": "9aba44ce-6377-42df-af30-a766c5758c13",
        "contentType": "STORY",
        "title": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall",
        "description": "",
        "summary": "The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.",
        "pubDate": "2025-11-06T16:39:36Z",
        "displayTime": "2025-11-06T16:40:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/fc55e1c0-bb2b-11f0-acfd-85500221de7f",
          "originalWidth": 4500,
          "originalHeight": 3000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/snkOq7ZRGEMlw358l6Qbmw--~B/aD0zMDAwO3c9NDUwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fc55e1c0-bb2b-11f0-acfd-85500221de7f.cf.webp",
              "width": 4500,
              "height": 3000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qv4mtGYShx_XW.HScYaSoA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fc55e1c0-bb2b-11f0-acfd-85500221de7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/astrazeneca-us-investment-new-york-listing-163936444.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/astrazeneca-us-investment-new-york-listing-163936444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:06:47+00:00",
    "headline": "Novo Nordisk again raises bid in battle for obesity start-up Metsera",
    "summary": "Novo Nordisk has once again sweetened its offer for obesity biotech Metsera, as the Ozempic maker trades back-and-forth bids with Pfizer in a...",
    "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
      "content": {
        "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
        "contentType": "STORY",
        "title": "Novo Nordisk again raises bid in battle for obesity start-up Metsera",
        "description": "",
        "summary": "Novo Nordisk has once again sweetened its offer for obesity biotech Metsera, as the Ozempic maker trades back-and-forth bids with Pfizer in a...",
        "pubDate": "2025-11-06T16:06:47Z",
        "displayTime": "2025-11-06T16:06:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:02:10+00:00",
    "headline": "Stocks to Watch Thursday: Marvell, Arm, Snap, DraftKings",
    "summary": "‚ÜóÔ∏è Marvell (MRVL): Japan's SoftBank (JP:9984) explored a potential takeover of the U.S. semiconductor maker, intending to merge it with Arm (ARM), Bloomberg reported. Marvell shares rose about 1%. Shares of Arm fell, despite the British chip maker's results and guidance topping forecasts.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
      "content": {
        "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
        "contentType": "STORY",
        "title": "Stocks to Watch Thursday: Marvell, Arm, Snap, DraftKings",
        "description": "",
        "summary": "‚ÜóÔ∏è Marvell (MRVL): Japan's SoftBank (JP:9984) explored a potential takeover of the U.S. semiconductor maker, intending to merge it with Arm (ARM), Bloomberg reported. Marvell shares rose about 1%. Shares of Arm fell, despite the British chip maker's results and guidance topping forecasts.",
        "pubDate": "2025-11-06T16:02:10Z",
        "displayTime": "2025-11-06T16:02:10Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a1ff4ab9-5bf1-31bc-a536-a49e1309d556/stocks-to-watch-thursday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/b97d05dd9895bc6d693d676a834ec796",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kHui7p4d089DIEpK31Z8YQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/b97d05dd9895bc6d693d676a834ec796.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X2bD0eAP0nf5QOhI1HscuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/b97d05dd9895bc6d693d676a834ec796.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DKNG"
            },
            {
              "symbol": "ARM"
            },
            {
              "symbol": "MRVL"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PENN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "PEAI.PVT"
            },
            {
              "symbol": "9984.T"
            },
            {
              "symbol": "DIS"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:36:41+00:00",
    "headline": "No Brainer Dividend Stocks To Buy Now",
    "summary": "You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential. Pfizer (NYSE: PFE), ... No Brainer Dividend Stocks To Buy Now",
    "url": "https://247wallst.com/investing/2025/11/06/no-brainer-dividend-stocks-to-buy-now/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3ec89163-fb43-382f-91f1-ccf16feb47c7",
      "content": {
        "id": "3ec89163-fb43-382f-91f1-ccf16feb47c7",
        "contentType": "STORY",
        "title": "No Brainer Dividend Stocks To Buy Now",
        "description": "",
        "summary": "You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential. Pfizer (NYSE: PFE), ... No Brainer Dividend Stocks To Buy Now",
        "pubDate": "2025-11-06T17:36:41Z",
        "displayTime": "2025-11-06T17:36:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/7f069e27c588f422b40b633cf697264c",
          "originalWidth": 2560,
          "originalHeight": 1842,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n0ezTkUo8Od_FBdTJqRExg--~B/aD0xODQyO3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/7f069e27c588f422b40b633cf697264c.cf.webp",
              "width": 2560,
              "height": 1842,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lMG4SBRvYhPdoK90YxbhqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/7f069e27c588f422b40b633cf697264c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/06/no-brainer-dividend-stocks-to-buy-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/no-brainer-dividend-stocks-buy-173641984.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UPS"
            },
            {
              "symbol": "O"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:14:22+00:00",
    "headline": "Why Novo Nordisk (CPSE:NOVO B) Is Down 10.1% After Lower Guidance and Restructuring Amid Wegovy Data",
    "summary": "On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new clinical data showing Wegovy‚Äôs benefits in lowering obesity-related health risks and pursuing regulatory approval for a higher dose. This period also saw heated legal battles with Pfizer over the acquisition of obesity biotech Metsera and the announcement of significant restructuring efforts,...",
    "url": "https://finance.yahoo.com/news/why-novo-nordisk-cpse-novo-171422983.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "03327e42-667e-3fdb-a972-6b6ff7febe14",
      "content": {
        "id": "03327e42-667e-3fdb-a972-6b6ff7febe14",
        "contentType": "STORY",
        "title": "Why Novo Nordisk (CPSE:NOVO B) Is Down 10.1% After Lower Guidance and Restructuring Amid Wegovy Data",
        "description": "",
        "summary": "On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new clinical data showing Wegovy‚Äôs benefits in lowering obesity-related health risks and pursuing regulatory approval for a higher dose. This period also saw heated legal battles with Pfizer over the acquisition of obesity biotech Metsera and the announcement of significant restructuring efforts,...",
        "pubDate": "2025-11-06T17:14:22Z",
        "displayTime": "2025-11-06T17:14:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-novo-nordisk-cpse-novo-171422983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-novo-nordisk-cpse-novo-171422983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:05:39+00:00",
    "headline": "Lilly, Novo to Lower Obesity Drug Prices in Deal With Trump",
    "summary": "The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials.  The companies‚Äô products will receive a three-year grace period from Trump‚Äôs forthcoming duties on pharmaceutical imports, an official said, similar terms to those clinched by their rivals in previous drug-price deals.",
    "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
      "content": {
        "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
        "contentType": "STORY",
        "title": "Lilly, Novo to Lower Obesity Drug Prices in Deal With Trump",
        "description": "",
        "summary": "The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials.  The companies‚Äô products will receive a three-year grace period from Trump‚Äôs forthcoming duties on pharmaceutical imports, an official said, similar terms to those clinched by their rivals in previous drug-price deals.",
        "pubDate": "2025-11-06T17:05:39Z",
        "displayTime": "2025-11-06T17:05:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gCZCsUJlU_eGSKICIOeYWw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WHyHD1H6zLz3nNV.CBM0Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "MRK.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:16:00+00:00",
    "headline": "Moderna‚Äôs Quarter Wasn‚Äôt As Bad as It Could Have Been. The Stock Is Up.",
    "summary": "Moderna‚Äôs  third-quarter results weren‚Äôt as bad as they could have been, which was enough to trigger a rally in the stock on Thursday.  Sales of Moderna‚Äôs respiratory syncytial virus, or RSV, vaccine remain negligible, and the company had a net loss of $200 million for the quarter.  The quarter‚Äôs revenue of $1 billion beat the  FactSet  consensus estimate of $900 million.",
    "url": "https://www.barrons.com/articles/moderna-stock-earnings-preview-51975438?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "0b5bfd14-9904-3099-a0a9-8b9596ae958e",
      "content": {
        "id": "0b5bfd14-9904-3099-a0a9-8b9596ae958e",
        "contentType": "STORY",
        "title": "Moderna‚Äôs Quarter Wasn‚Äôt As Bad as It Could Have Been. The Stock Is Up.",
        "description": "",
        "summary": "Moderna‚Äôs  third-quarter results weren‚Äôt as bad as they could have been, which was enough to trigger a rally in the stock on Thursday.  Sales of Moderna‚Äôs respiratory syncytial virus, or RSV, vaccine remain negligible, and the company had a net loss of $200 million for the quarter.  The quarter‚Äôs revenue of $1 billion beat the  FactSet  consensus estimate of $900 million.",
        "pubDate": "2025-11-06T16:16:00Z",
        "displayTime": "2025-11-06T16:16:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0b5bfd14-9904-3099-a0a9-8b9596ae958e/moderna%E2%80%99s-quarter-wasn%E2%80%99t-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/749fjdDNHOZZaiWMxvk7TQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rrBpMbNzvxDHGSjZc1Bgxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/moderna-stock-earnings-preview-51975438?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:34:00+00:00",
    "headline": "Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market",
    "summary": "The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.",
    "url": "https://www.barrons.com/articles/novo-nordisk-eli-lilly-weight-loss-drugs-medicare-trump-a0b02e56?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "800f8cc9-50dd-36cc-ad8b-9fd66b1d008c",
      "content": {
        "id": "800f8cc9-50dd-36cc-ad8b-9fd66b1d008c",
        "contentType": "STORY",
        "title": "Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market",
        "description": "",
        "summary": "The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.",
        "pubDate": "2025-11-06T18:34:00Z",
        "displayTime": "2025-11-06T18:34:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/800f8cc9-50dd-36cc-ad8b-9fd66b1d008c/novo-nordisk-and-eli-lilly.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
          "originalWidth": 320,
          "originalHeight": 65,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dzJ1YBP0KGeG_11a2M96gg--~B/aD02NTt3PTMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 320,
              "height": 65,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yw_3eAv_WYSK2a6PV_FD9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-eli-lilly-weight-loss-drugs-medicare-trump-a0b02e56?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:45:00+00:00",
    "headline": "AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform",
    "summary": "AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.",
    "url": "https://finance.yahoo.com/news/azn-q3-earnings-top-estimates-164500415.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d0cc7c5f-8913-3439-a91d-d35e36f501fb",
      "content": {
        "id": "d0cc7c5f-8913-3439-a91d-d35e36f501fb",
        "contentType": "STORY",
        "title": "AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform",
        "description": "",
        "summary": "AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.",
        "pubDate": "2025-11-06T16:45:00Z",
        "displayTime": "2025-11-06T16:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffSS19YaoL36xXdlr0Ip4A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJhhM1.2_VWzkATXxZYL_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/azn-q3-earnings-top-estimates-164500415.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/azn-q3-earnings-top-estimates-164500415.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T19:20:13+00:00",
    "headline": "Jim Cramer Highlights the Woes of Pfizer and the Drug Sector",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer‚Äôs radar. Cramer noted that the company could not perform as its entire industry is going through a tough time. He remarked: ‚Äú‚Ä¶We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are historically [‚Ä¶]",
    "url": "https://finance.yahoo.com/news/jim-cramer-highlights-woes-pfizer-192013377.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "6a93730a-2af9-34c1-97b5-8111686e8f37",
      "content": {
        "id": "6a93730a-2af9-34c1-97b5-8111686e8f37",
        "contentType": "STORY",
        "title": "Jim Cramer Highlights the Woes of Pfizer and the Drug Sector",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer‚Äôs radar. Cramer noted that the company could not perform as its entire industry is going through a tough time. He remarked: ‚Äú‚Ä¶We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are historically [‚Ä¶]",
        "pubDate": "2025-11-06T19:20:13Z",
        "displayTime": "2025-11-06T19:20:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lBNvOkwEcDTC6JSi8u6u5Q--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l4R272WQ4gg_U7DbC5QzrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-highlights-woes-pfizer-192013377.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-highlights-woes-pfizer-192013377.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T19:19:58+00:00",
    "headline": "Jim Cramer Recommends Eli Lilly Over Viking Therapeutics",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: ‚ÄúYeah, I know, and I‚Äôve watched that, and I don‚Äôt, I think [‚Ä¶]",
    "url": "https://finance.yahoo.com/news/jim-cramer-recommends-eli-lilly-191958282.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e5ee382b-8e27-3302-8b8d-4b868de9bc5a",
      "content": {
        "id": "e5ee382b-8e27-3302-8b8d-4b868de9bc5a",
        "contentType": "STORY",
        "title": "Jim Cramer Recommends Eli Lilly Over Viking Therapeutics",
        "description": "",
        "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: ‚ÄúYeah, I know, and I‚Äôve watched that, and I don‚Äôt, I think [‚Ä¶]",
        "pubDate": "2025-11-06T19:19:58Z",
        "displayTime": "2025-11-06T19:19:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E2lv2kKRF2jXt8F.V84xVw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BN9PfJYu5RffW4DiInJR2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-recommends-eli-lilly-191958282.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-recommends-eli-lilly-191958282.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:58:00+00:00",
    "headline": "Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans",
    "summary": "MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment",
    "url": "https://finance.yahoo.com/news/moderna-q3-earnings-beat-stock-165800532.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a8f0e03b-f9f5-347d-9f54-9a4fdf231287",
      "content": {
        "id": "a8f0e03b-f9f5-347d-9f54-9a4fdf231287",
        "contentType": "STORY",
        "title": "Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans",
        "description": "",
        "summary": "MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment",
        "pubDate": "2025-11-06T16:58:00Z",
        "displayTime": "2025-11-06T16:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/e57c38ef2cab6e9081bde6f59c7a4095",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E9t3mk6J0lesVKcjZ2SgQA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e57c38ef2cab6e9081bde6f59c7a4095.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iEzDa9vreyHFcwlV4oyI1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e57c38ef2cab6e9081bde6f59c7a4095.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-q3-earnings-beat-stock-165800532.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-q3-earnings-beat-stock-165800532.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T20:23:49+00:00",
    "headline": "Novo Nordisk challenges Pfizer to raise offer for obesity biotech Metsera",
    "summary": "Novo Nordisk‚Äôs chief executive challenged Pfizer to increase its bid for obesity start-up Metsera, as the Denmark-based drugmaker again bested...",
    "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
      "content": {
        "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
        "contentType": "STORY",
        "title": "Novo Nordisk challenges Pfizer to raise offer for obesity biotech Metsera",
        "description": "",
        "summary": "Novo Nordisk‚Äôs chief executive challenged Pfizer to increase its bid for obesity start-up Metsera, as the Denmark-based drugmaker again bested...",
        "pubDate": "2025-11-06T20:23:49Z",
        "displayTime": "2025-11-06T20:23:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T20:02:00+00:00",
    "headline": "Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments.",
    "summary": "Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.",
    "url": "https://www.barrons.com/articles/biotech-mergers-cvr-stocks-ff1e996d?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "c1ee16da-fae9-3f10-b045-7efdd08aecc5",
      "content": {
        "id": "c1ee16da-fae9-3f10-b045-7efdd08aecc5",
        "contentType": "STORY",
        "title": "Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments.",
        "description": "",
        "summary": "Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.",
        "pubDate": "2025-11-06T20:02:00Z",
        "displayTime": "2025-11-06T20:02:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c1ee16da-fae9-3f10-b045-7efdd08aecc5/biotech-m-a-deals-are.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3c42eb23f3229e8d0dd693d3475a00fc",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/owJegMBKWgwTJHrVLQe5eQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3c42eb23f3229e8d0dd693d3475a00fc.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wj9vIokfXBbFZZGVwp3wcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3c42eb23f3229e8d0dd693d3475a00fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-mergers-cvr-stocks-ff1e996d?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "AKRO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:34:02+00:00",
    "headline": "3 Value Stocks That Fall Short",
    "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they‚Äôre out of favor. The key risk, however, is that these stocks are usually cheap for a reason ‚Äì five cents for a piece of fruit may seem like a great deal until you find out it‚Äôs rotten.",
    "url": "https://finance.yahoo.com/news/3-value-stocks-fall-short-183402705.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "68cae34d-6e69-382d-bc59-cce0efdd9e26",
      "content": {
        "id": "68cae34d-6e69-382d-bc59-cce0efdd9e26",
        "contentType": "STORY",
        "title": "3 Value Stocks That Fall Short",
        "description": "",
        "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they‚Äôre out of favor. The key risk, however, is that these stocks are usually cheap for a reason ‚Äì five cents for a piece of fruit may seem like a great deal until you find out it‚Äôs rotten.",
        "pubDate": "2025-11-06T18:34:02Z",
        "displayTime": "2025-11-06T18:34:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1973b77b1723c57555fa13f39f52be07",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "SIRI Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QhWa6whE2u_fvczsuTO57A--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1973b77b1723c57555fa13f39f52be07.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7fDiJPSyqk6rqfmM3gYqQA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1973b77b1723c57555fa13f39f52be07.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-value-stocks-fall-short-183402705.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-value-stocks-fall-short-183402705.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SIRI"
            },
            {
              "symbol": "SEE"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T20:59:27+00:00",
    "headline": "Eli Lilly, Novo Nordisk to Cut Drug Prices, Get Tariff Relief Under Deals With Trump Administration",
    "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe",
    "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-205927557.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "39ff2f6a-b4ad-3e8d-94af-974184c8615a",
      "content": {
        "id": "39ff2f6a-b4ad-3e8d-94af-974184c8615a",
        "contentType": "STORY",
        "title": "Eli Lilly, Novo Nordisk to Cut Drug Prices, Get Tariff Relief Under Deals With Trump Administration",
        "description": "",
        "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe",
        "pubDate": "2025-11-06T20:59:27Z",
        "displayTime": "2025-11-06T20:59:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "pillsdrugspharmacy - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_47DdDax2mFqu9DGfd1IHg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.2HxBgHtuHXuuB3ZiLaY3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-205927557.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-205927557.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T22:30:00+00:00",
    "headline": "Trump inks Eli Lilly & Novo deals: How to play pharma stocks",
    "summary": "US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "769e7adf-e9cc-3ea5-84c7-c65dbab0e6d4",
      "content": {
        "id": "769e7adf-e9cc-3ea5-84c7-c65dbab0e6d4",
        "contentType": "VIDEO",
        "title": "Trump inks Eli Lilly & Novo deals: How to play pharma stocks",
        "description": "<p>US President Trump announced deals with Novo Nordisk (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) and Eli Lilly (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>) to secure lower prices of the companies' GLP-1 drugs.</p>\n<p>Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/author/josh-lipton/\">Josh Lipton</a> to take a closer look at what the deals mean for the companies.</p>\n<p>Breen also discusses Pfizer's (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>) legal case to block Novo Nordisk's (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) Metsera (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/MTSR\">MTSR</a>) acquisition.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-domination-overtime/\">Market Domination Overtime</a>.</p>",
        "summary": "US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
        "pubDate": "2025-11-06T22:30:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/fd7d82f0-bb59-11f0-9bee-5bf59c188809",
          "originalWidth": 7390,
          "originalHeight": 4161,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SrpCArzSoYHL3BazC.HdrQ--~B/aD00MTYxO3c9NzM5MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fd7d82f0-bb59-11f0-9bee-5bf59c188809.cf.webp",
              "width": 7390,
              "height": 4161,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bpg8katqiAezzsIF3339xw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fd7d82f0-bb59-11f0-9bee-5bf59c188809.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T20:23:49+00:00",
    "headline": "Novo Nordisk challenges Pfizer to raise offer for obesity biotech",
    "summary": "Novo Nordisk‚Äôs chief executive challenged Pfizer to increase its bid for obesity start-up Metsera, as the Denmark-based drugmaker again bested...",
    "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
      "content": {
        "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
        "contentType": "STORY",
        "title": "Novo Nordisk challenges Pfizer to raise offer for obesity biotech",
        "description": "",
        "summary": "Novo Nordisk‚Äôs chief executive challenged Pfizer to increase its bid for obesity start-up Metsera, as the Denmark-based drugmaker again bested...",
        "pubDate": "2025-11-06T20:23:49Z",
        "displayTime": "2025-11-06T20:23:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]